• Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
CASE REPORT
Year : 2016  |  Volume : 2  |  Issue : 3  |  Page : 90-94

Combined Chronic Lymphocytic Leukemia and Pancreatic Neuroendocrine Carcinoma: A Collision Tumor Variation


1 Department of Medicine, NYU Lutheran Medical Center, Brooklyn, NY, USA
2 Department of Pathology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY, USA
3 Division of Hematology-Oncology, NYU Lutheran Medical Center, Brooklyn, NY, USA

Correspondence Address:
Dr. Panagiotis J Vlachostergios
Department of Medicine, NYU Lutheran Medical Center, 150 55th Street, Brooklyn, NY 11220
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2395-3977.184321

Rights and Permissions

Chronic lymphocytic leukemia (CLL)-induced immunodeficiency has been implicated in the occurrence of several secondary or concurrent malignancies. We hereby present the first case of combined CLL and pancreatic neuroendocrine tumor as collision neoplasms within metastatic periportal lymphadenopathy in a 62-year-old patient who presented with obstructive jaundice. An ovoid nodular mass was seen posterior to the head of the pancreas on magnetic resonance cholangiopancreatography and the patient subsequently underwent endoscopic retrograde cholangiopancreatography, with successful placement of two stents within the identified hilar stricture. Tn-111 pentetreotide scintigraphy with single-photon emission computed tomography (CT)/CT disclosed two foci of somatostatin receptor positive tissue in the upper abdomen correlating to the previously seen porta hepatis and portacaval lymphadenopathy and the patient was treated with octreotide. Simultaneous onset of CLL and secondary malignancies that each has a different disease status is a rare phenomenon but is important to diagnose for establishing an appropriate treatment strategy, which in certain cases may involve the use of agents active in both types of malignancy to minimize toxicity.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3578    
    Printed60    
    Emailed0    
    PDF Downloaded216    
    Comments [Add]    

Recommend this journal